So, talk about some of the take-home key treatment changes that are taking place.

Sure.

So I think big picture, break it down.

Category A and B, we're gonna treat together.

Category C, D, and E, we're gonna treat together, okay? So category A, again, is that asymptomatic patient who just happens to have a small subsegmental PE, right? That patient can go home, assuming there's nothing else going on.

That patient can go home on anticoagulation.

Category B as well is a low risk patient by one of the three clinical severity scores that they recommend now.

So let's talk about the changes in terms of the wake-ups.

There are a lot of people in New Zealand who'd love to do that, but finding it really hard to get into the big guys.

Yeah, yeah.

We definitely have got a foothold in New Zealand in the last couple of years, which has been super exciting because we started on that D2C e-commerce channel.

And then as we started growing, it's like a two-way relationship with those retailers.

And we love partnering with the retailers, but to actually have their trust, they need to know that you're actually going to sell off the shelf and that you've got this community that Tom talks about who will go in there and want to buy your two dudes products.

So we've been able to over the last couple of years form these amazing relationships with the retailers in New Zealand to then actually help us break into the Australian market.

What would your advice be for others who would like to firstly break into the New Zealand market more, but also then take the step that you have and try and get in to the Australian market? I

think there's two pieces of advice.